Tetraprenylacetone promotes healing process of ethanol-induced gastric damage in the rat

Efficacy of teprenone in treatment of chronic atrophic gastritis: an analysis of 100 cases

AIM: To explore the clinical efficacy of teprenone in the treatment of chronic atrophic gastritis (CAG).

METHODS: A total of 100 patients with CAG were chosen by endoscopic examination. A random, prospective and self control method was used. H pylori-positive patients received routine sterilization first, and then all the patients took teprenone for 24 wk. The clinical symptoms before and 4, 12 and 24 wk after therapy were evaluated, and endoscopic examination was performed before and 12 and 24 wk after therapy for pathological observation.

RESULTS: Clinical symptoms were significantly different before and after treatment (P < 0.05). The endoscopic results, pathological findings before and after therapy also had significant differences (P < 0.05). There were no marked differences in the above three aspects between H pylori-positive and -negative patients. After therapy, particles became thinner and metaplastic nodes diminished, together with obvious improvement of tissue pathology under endoscope.

CONCLUSION: Teprenone can relieve the clinical symptoms, endoscopic and pathological findings of CAG patients. Meanwhile, teprenone is convenient to use, with few side effects.

Teprenone, an anti-ulcer agent, increases gastric mucosal mucus level via nitric oxide in rats

We examined whether the increasing action of teprenone (TP) on mucus synthesis and content in rat gastric mucosa is related to nitric oxide (NO) formation via NO synthase (NOS) in the tissue. TP (200 mg/kg)-induced increases in levels of gastric mucosal hexosamine and adherent mucus were inhibited with decreased gastric mucosal NOS activity and nitrite/nitrate concentration by co-administration of NG-monomethyl L-arginine (100 mg/kg), a NOS inhibitor, but not its D-isomer. These results suggest that TP exerts an increasing action on gastric mucus synthesis and content possibly under the condition of maintained NO production via NOS in gastric mucosal tissues, although the precise mechanisms for the action of TP is still unclear.

Protective and preventive effects of teprenone on gastric mucosal lesions in rats

We have reported that neutrophil infiltration into gastric mucosa is closely related to gastric mucosal lesion development in rats with water immersion restraint stress. In this study, we examined the effect of teprenone, which is known to prevent gastric mucosal injury through stimulation of gastric mucus synthesis and secretion, on neutrophil infiltration into the gastric mucosa of rats with water immersion restraint stress. Pre- and post-administration of teprenone (200 mg/kg, p.o.) significantly attenuated the neutrophil infiltration into the gastric mucosa and the lesion development found at 6 h of water immersion restraint stress with preservation of gastric mucosal hexosamine and adherent mucus levels. These results indicate that teprenone exerts protective and preventive actions against water immersion restraint stress-induced gastric mucosal lesions in rats and suggest that these actions could be related to the preservation of gastric mucus synthesis and secretion and inhibition of neutrophil infiltration into the gastric mucosal tissue.